Revista médica de Chile
-
Revista médica de Chile · Oct 2022
[Off-label use of mycophenolate mofetil in immune-mediated diseases].
Mycophenolate mofetil (MMF) is a largely used immunosuppressive agent in the prevention of transplant rejection and lupus nephritis. Its use has been extended to other immune-mediated diseases (ID). ⋯ Mycophenolate has a favorable response profile as a second line immunosuppressive agent. It is effective as a glucocorticoid sparing drug. The safety profile is also favorable as adverse effects were scanty and mild.
-
Musculoskeletal tumors are uncommon. However, the true burden of all bone and soft tissue tumors of extremities is underestimated. ⋯ Therefore, an adequate clinical and radiological assessment, along with the awareness and application of simple guidelines for referral to a specialized center, are of utmost importance. These are critical steps for an appropriate diagnosis and treatment of sarcomas, improving their prognosis.
-
Revista médica de Chile · Oct 2022
[Proposal of an informed consent form to obtain audiovisual material from patients].
An informed consent is mandatory to obtain any clinical audiovisual material from patients. Although there are some documents created for this purpose, there are some barriers for their application, such as the context in which they were created, the language and download availability. ⋯ The proposed ICFs were liberated for their use among health care professionals in Chile, who could use them, provided that they are approved by the local healthcare ethics committees.
-
Revista médica de Chile · Oct 2022
[Clinical features of Chilean patients with Fibrous Dysplasia/McCune-Albright Syndrome].
Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is characterized by a spectrum of manifestations that may include fibrous dysplasia of bone and multiple endocrinopathies. ⋯ These patients demonstrate the variable nature of the clinical presentation and study of FD/MAS. It is essential to increase the index of diagnostic suspicion and adherence to international recommendations.
-
Revista médica de Chile · Oct 2022
[Profile of glucose lowering drug use in outpatients with type 2 diabetes mellitus].
The use of glucose lowering agents with favorable weight profile is a growing practice in Diabetology. ⋯ The use of SGLT2i and GLP1ra in patients with T2D is associated with better metabolic control than rapid insulin with less risk of hypoglycemia. The use of these therapies should be prioritized in the future.